-
4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine hydrochloride
-
ChemBase ID:
154910
-
Molecular Formular:
C31H37ClN4O6
-
Molecular Mass:
597.10168
-
Monoisotopic Mass:
596.2401626
-
SMILES and InChIs
SMILES:
COc1ccc(cc1OC)CCNc1nc2cc(c(cc2c(n1)N1CCc2cc(c(cc2C1)OC)OC)OC)OC.Cl
Canonical SMILES:
COc1cc2nc(NCCc3ccc(c(c3)OC)OC)nc(c2cc1OC)N1CCc2c(C1)cc(c(c2)OC)OC.Cl
InChI:
InChI=1S/C31H36N4O6.ClH/c1-36-24-8-7-19(13-25(24)37-2)9-11-32-31-33-23-17-29(41-6)28(40-5)16-22(23)30(34-31)35-12-10-20-14-26(38-3)27(39-4)15-21(20)18-35;/h7-8,13-17H,9-12,18H2,1-6H3,(H,32,33,34);1H
InChIKey:
WWCHXVYTCMPAMV-UHFFFAOYSA-N
-
Cite this record
CBID:154910 http://www.chembase.cn/molecule-154910.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine hydrochloride
|
|
|
IUPAC Traditional name
|
4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine hydrochloride
|
|
|
Synonyms
|
4-(3,4-Dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxy-2-quinazolinamine monohydrochloride
|
CP-100356 monohydrochloride
|
CP-100356 Hydrochloride
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
16.594355
|
H Acceptors
|
10
|
H Donor
|
1
|
LogD (pH = 5.5)
|
3.6596088
|
LogD (pH = 7.4)
|
4.918264
|
Log P
|
5.1105967
|
Molar Refractivity
|
159.7514 cm3
|
Polarizability
|
60.93138 Å3
|
Polar Surface Area
|
96.43 Å2
|
Rotatable Bonds
|
11
|
Lipinski's Rule of Five
|
false
|
DETAILS
DETAILS
Sigma Aldrich
TRC
Sigma Aldrich -
PZ0171
|
Legal Information Sold for research purposes under agreement from Pfizer Inc. Biochem/physiol Actions CP-100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter. The compound has low uM to nM potency for inhibiting several MDR-1 substrates (calcein-AM, digoxin) in transfected MDCKII cells. CP-100356 also inhibits prazosin transport in human breast cancer resistance protein (BCRP)-transfected MDCKII cells, suggesting that it acts as a dual inhibitor. CP-100356 does not inhibit multidrug resistance-associated protein 2 (MPR2 IC50 >15 mM). |
Toronto Research Chemicals -
C781250
|
CP-100356 is a specific inhibitor of MDR1 (P-Gp), the protypical ABC transporter. CP-100356 also inhibits prazosin transport in human breast cancer resistance protein (BCRP)-transfected MDCKII cells, suggesting that it acts as a dual inhibitor. CP-100356 |
REFERENCES
REFERENCES
From Suppliers
Google Scholar
PubMed
Google Books
- • Ayrton, A., et al.: Xenobiotica, 31, 469 (2001)
- • Mizuno, N., et al.: Pharmacol. Rev., 55, 425 (2001)
- • Fojo, T., et al.: Clin. Breast Cancer, 7, 749 (2001)
- • Polli, J., et al.: Drug Metab. Dispos., 36, 695 92008),
- Searching...Please wait...
PATENTS
PATENTS
PubChem Patent
Google Patent